Insmed (INSM) Cash from Operations Growth (5y) (2015 - 2026)

Insmed (INSM) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 69,146.49 Bn 69,146.20 Bn -
2 Nanobiotix 1,942.19 Bn 1,942.13 Bn -
3 Akari Therapeutics 1,132.35 Bn 1,132.35 Bn -
4 BeOne Medicines 475.42 Bn 470.63 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.32 Bn 116.08 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.80 Bn 61.04 Bn 3.31 Bn
7 Belite Bio 63.28 Bn 63.28 Bn -
8 Argenx Se 56.67 Bn 51.48 Bn 1.41 Bn
9 Revolution Medicines 38.15 Bn 38.15 Bn -
10 Insmed 23.05 Bn 21.83 Bn 258.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -11.67%
Dec 31, 2025 -29.96%
Sep 30, 2025 -30.23%
Jun 30, 2025 -41.72%
Mar 31, 2025 -35.24%
Dec 31, 2024 -34.57%
Sep 30, 2024 -28.14%
Jun 30, 2024 -8.97%
Mar 31, 2024 -20.04%
Dec 31, 2023 -13.27%
Sep 30, 2023 -15.79%
Jun 30, 2023 -17.46%
Mar 31, 2023 -16.76%
Dec 31, 2022 -16.42%
Sep 30, 2022 -18.63%
Jun 30, 2022 -23.06%
Mar 31, 2022 -23.29%
Dec 31, 2021 -7.74%
Sep 30, 2021 -19.48%
Jun 30, 2021 -21.72%